Somnomed Ltd
ASX:SOM
Intrinsic Value
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. [ Read More ]
The intrinsic value of one SOM stock under the Base Case scenario is 1.036 AUD. Compared to the current market price of 0.385 AUD, Somnomed Ltd is Undervalued by 63%.
Valuation Backtest
Somnomed Ltd
Run backtest to discover the historical profit from buying and selling SOM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Somnomed Ltd
Current Assets | 30.2m |
Cash & Short-Term Investments | 12.8m |
Receivables | 12.6m |
Other Current Assets | 4.8m |
Non-Current Assets | 33.7m |
PP&E | 12m |
Intangibles | 18.8m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 17.5m |
Accounts Payable | 11.3m |
Short-Term Debt | 309.3k |
Other Current Liabilities | 5.8m |
Non-Current Liabilities | 16.6m |
Long-Term Debt | 15.7m |
Other Non-Current Liabilities | 870.2k |
Earnings Waterfall
Somnomed Ltd
Revenue
|
88.8m
AUD
|
Cost of Revenue
|
-34m
AUD
|
Gross Profit
|
54.8m
AUD
|
Operating Expenses
|
-61.3m
AUD
|
Operating Income
|
-6.5m
AUD
|
Other Expenses
|
-4.1m
AUD
|
Net Income
|
-10.6m
AUD
|
Free Cash Flow Analysis
Somnomed Ltd
What is Free Cash Flow?
SOM Profitability Score
Profitability Due Diligence
Somnomed Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Somnomed Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
SOM Solvency Score
Solvency Due Diligence
Somnomed Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Somnomed Ltd's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SOM Price Targets Summary
Somnomed Ltd
According to Wall Street analysts, the average 1-year price target for SOM is 1.275 AUD with a low forecast of 1.263 AUD and a high forecast of 1.313 AUD.
Shareholder Return
SOM Price
Somnomed Ltd
Average Annual Return | -0.22% |
Standard Deviation of Annual Returns | 45.87% |
Max Drawdown | -90% |
Market Capitalization | 41.8m AUD |
Shares Outstanding | 108 591 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
Contact
IPO
Employees
Officers
The intrinsic value of one SOM stock under the Base Case scenario is 1.036 AUD.
Compared to the current market price of 0.385 AUD, Somnomed Ltd is Undervalued by 63%.